Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Convergen Logo
Convergen Growth Score
90
CB Rank
64847
Heat Score
16
Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases.
Founded
obfuscation
PrivateSeed Suzhou, Jiangsu, China11-50 www.convergenbio.com/
Biotechnology
Manufacturing
Pharmaceutical
Overview

Convergen
Total Funding
obfuscation
Growth Score
90
Heat Score
16

Total Funding
obfuscation
obfuscation
Seed raised
obfuscation
Growth Score90
-3 pts
in past quarter
Heat Score 16
-15 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Convergen

CB Rank
64847
Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases.
Founded
obfuscation
PrivateSeed Suzhou, Jiangsu, China11-50 www.convergenbio.com/
Biotechnology
Manufacturing
Pharmaceutical

Funding Rounds

Seed
OBF
in
obfuscation

Key People

Details

Legal Name Convergen(SuZhou)Pharmaceutical Co., Ltd.
Also Known As Convergen Pharmaceuticals
Operating Status Active
Company Type For Profit
Founders  Jinquan Sun
About the Company
Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases and other conditions driven by protein aggregates
Predictions & Insights

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Runway Speculation

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Convergen Logo
Seed Round - Convergen
1
obfuscation
Qiming Venture PartnersSeed
obfuscation
Seed Round - Convergen Logo
Seed Round - Convergen
1
obfuscation
Qiming Venture PartnersSeed
obfuscation
Seed Round - Convergen Logo
Seed Round - Convergen
1
obfuscation
Qiming Venture PartnersSeed
obfuscation
Seed Round - Convergen Logo
Seed Round - Convergen
1
obfuscation
Qiming Venture PartnersSeed
obfuscation
Seed Round - Convergen Logo
Seed Round - Convergen
1
obfuscation
Qiming Venture PartnersSeed

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Convergen Logo
Seed Round - Convergen
1
obfuscation
Qiming Venture PartnersSeed
obfuscation
Seed Round - Convergen Logo
Seed Round - Convergen
1
obfuscation
Qiming Venture PartnersSeed
obfuscation
Seed Round - Convergen Logo
Seed Round - Convergen
1
obfuscation
Qiming Venture PartnersSeed
obfuscation
Seed Round - Convergen Logo
Seed Round - Convergen
1
obfuscation
Qiming Venture PartnersSeed
obfuscation
Seed Round - Convergen Logo
Seed Round - Convergen
1
obfuscation
Qiming Venture PartnersSeed

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 1

Employee Profiles

News

News and Press

News•Dec 16, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Active Website Tech Count

3Convergen is actively using 3 technologies for its website, according to BuiltWith. These include SSL by Default, CommonCrawl Top 50m, and  Euro.
Sub-Organizations
Frequently Asked Questions

Where is Convergen's headquarters? Convergen is located in Suzhou, Jiangsu, China.Who invested in Convergen? Convergen is funded by Qiming Venture Partners.When was the last funding round for Convergen? Convergen closed its last funding round on
obfuscation
from a Seed round.Who are Convergen's competitors? Alternatives and possible competitors to Convergen may include Monte Rosa Therapeutics, Arvinas, and  Foghorn Therapeutics.How much funding has Convergen raised to date? Convergen has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(411cf44 1)
|